Dlx-2 Activators represent a class of chemical compounds that directly or indirectly enhance the functional activity of Dlx-2, a transcription factor involved in embryonic development and cellular differentiation. These compounds act on a range of signaling pathways or biological processes that Dlx-2 is involved in, leading to increased functional activity of the protein. The specific effects of these compounds on Dlx-2 vary, but they all result in some form of increased activity, either directly or indirectly. Some Dlx-2 activators, such as retinoic acid, forskolin, PGE2, and IBMX, act by triggering specific pathways that result in upregulation of Dlx-2 expression. For instance, retinoic acid binds to the Retinoic Acid Receptor (RAR), which can then bind to the retinoic acid response element in the Dlx-2 promoter, leading to increased Dlx-2 expression. On the other hand, other Dlx-2 activators such as EGF, PD98059, LY294002, staurosporine, curcumin, resveratrol, genistein, and rapamycin, exert their effects by altering the balance of signaling pathways in a way that potentially favors Dlx-2 activation. For example,EGF activates the EGF receptor (EGFR) pathway, leading to the activation of downstream pathways such as the PI3K/AKT pathway, which enhances Dlx-2 activity due to its role in AKT phosphorylation. Similarly, curcumin inhibits NF-κB, indirectly enhancing Dlx-2 activity by reducing the competition for shared coactivators.
In the case of compounds like PD98059, LY294002, staurosporine, genistein, and rapamycin, these molecules interfere with key components of cellular signaling. Inhibition of these components can cause a shift in the balance of cellular signaling, favoring those pathways that enhance Dlx-2 activity. For example, PD98059 inhibits MEK, a key component of the ERK pathway, potentially favoring other pathways that enhance Dlx-2 activity such as the PI3K/AKT pathway. Similarly, rapamycin inhibits mTOR, a master regulator of cellular metabolism, again potentially favoring those pathways that enhance Dlx-2 activity. In essence, the Dlx-2 activators function by interacting with various cellular signaling components, leading to a milieu that promotes Dlx-2 functional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid can activate the Retinoic Acid Receptor (RAR), which can upregulate the expression of Dlx-2. This is due to the presence of a retinoic acid response element in the Dlx-2 gene promoter. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, elevating cAMP levels which in turn activate the PKA pathway. This pathway can phosphorylate the CREB protein, which can bind to the CREB response element in the Dlx-2 promoter, increasing Dlx-2 activity. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 can activate the EP2 receptor, leading to activation of the PKA pathway. This can result in the phosphorylation of CREB, which binds to the CREB response element in the Dlx-2 promoter, leading to enhanced Dlx-2 activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits phosphodiesterase, leading to increased cAMP levels. This activates the PKA pathway, leading to phosphorylation of CREB which can bind to the CREB response element in the Dlx-2 promoter, enhancing Dlx-2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, a component of the ERK pathway. This can lead to decreased ERK activity, altering the balance of signaling pathways, potentially favoring those that enhance Dlx-2 activity such as the PI3K/AKT pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, a key component of the PI3K/AKT pathway. When inhibited, it can alter the balance of signaling pathways, potentially favoring those that enhance Dlx-2 activity such as the ERK pathway. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits PKC, potentially leading to an imbalance of signaling pathways. This imbalance can favor pathways that enhance Dlx-2 activity, such as the PI3K/AKT pathway. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin is known to inhibit NF-κB, which can indirectly lead to enhanced Dlx-2 activity by reducing the competition for shared coactivators. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol activates SIRT1, which can enhance FOXO transcription factors. These factors can bind to FOXO response elements in the Dlx-2 promoter, leading to enhanced Dlx-2 activation. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein can inhibit tyrosine kinases, leading to an alteration in the balance of signaling pathways. This alteration can favor pathways that enhance Dlx-2 activity, such as the PI3K/AKT pathway. | ||||||